Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease

被引：0
|
作者：
Meri Tarockoff
Teresita Gonzalez
Stanislav Ivanov
Jose Sandoval-Sus
机构：
[1] Memorial Healthcare System,Department of Hematology and Oncology
[2] Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System Memorial Cancer Institute,undefined
来源：
Current Oncology Reports | 2022年 / 24卷
关键词：
Mantle cell lymphoma; Relapsed/refractory mantle cell lymphoma; Targeted therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：1313 / 1326
页数：13
相关论文
共 50 条
  • [41] Risk-adapted therapy for infantile myofibromatosis in children
    Levine, Emmanuelle
    Freneaux, Paul
    Schleiermacher, Gudrun
    Brisse, Herve
    Pannier, Stephanie
    Teissier, Natacha
    Mesples, Bettina
    Orbach, Daniel
    PEDIATRIC BLOOD & CANCER, 2012, 59 (01) : 115 - 120
  • [42] Bendamustine therapy for relapsed or refractory low grade B cell lymphoma and mantle cell lymphoma
    Yamada, Toshiki
    Shibata, Yuhei
    Nakamura, Nobuhiko
    Kitagawa, Jun-ichi
    Kanemura, Nobuhiro
    Kasahara, Senji
    Goto, Hideko
    Fukuno, Kenji
    Sawada, Michio
    Tsurumi, Hisashi
    ANNALS OF ONCOLOGY, 2015, 26 : 109 - 109
  • [43] Risk-adapted therapy in acute myeloid leukemia
    Fiegl, M.
    Hiddemann, W.
    INTERNIST, 2012, 53 (04): : 392 - +
  • [44] Risk-adapted treatment according to minimal residual disease in adult ALL
    Gökbuget, N
    Kneba, M
    Raff, T
    Bruggemann, M
    Scheuring, U
    Reutzel, R
    Hoelzer, D
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2002, 15 (04) : 639 - 652
  • [45] Future perspectives of radiation therapy for Hodgkin Lymphoma: Risk-adapted, response-adapted, and safer than before
    Saddi, Jessica
    Barcellini, Amelia
    Gotti, Manuel
    Mazzacane, Alessandro
    Tolva, Alessandra
    Lazic, Tanja
    Arcaini, Luca
    Zecca, Marco
    Orlandi, Ester
    Filippi, Andrea Riccardo
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (03)
  • [46] Targeted Early Detection and risk-adapted Therapy
    Bokemeyer, Carsten
    Engert, Andreas
    Goekbuget, Nadja
    Schmutzler, Rita
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 2 - 13
  • [47] Emerging Therapy for the Treatment of Mantle Cell Lymphoma
    Rajguru, Saurabh
    Kahl, Brad S.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (09): : 1311 - 1318
  • [48] Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma
    Mussetti, Alberto
    Kumar, Anita
    Dahi, Parastoo B.
    Perales, Miguel-Angel
    Sauter, Craig S.
    BLOOD REVIEWS, 2015, 29 (03) : 143 - 152
  • [49] Risk-adapted adjuvant treatment of colon cancer
    Reinacher-Schick, A.
    GASTROENTEROLOGE, 2012, 7 (01): : 14 - 23
  • [50] Risk-adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma
    Vorobyev, V., I
    Gemdzhian, E. G.
    Dubrovin, E., I
    Nesterova, E. S.
    Kaplanov, K. D.
    Volodicheva, E. M.
    Zherebtsova, V. A.
    Kravchenko, S. K.
    TERAPEVTICHESKII ARKHIV, 2019, 91 (07): : 41 - 51
12345